Medical Marijuana Inc. Receives New Chinese Patent

Medical Marijuana Inc. is the first cannabis company to be publicly traded in the United States. The company that is credited for the launch of the pioneering cannabis-derived nutraceutical merchandises, brands, and supply chain, today announced the issuance of Chinese Patent CN106456573B specifically for “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” to the portfolio investment subsidiary of the Company, Kannalife, Inc. This Patent is an addition to the long list of the patents’ portfolio of cannabidiol (CBD)-like molecules acquired by Kannalife.

CBD-like molecules (“KLS Family”), which are the intellectual property of Kannalife, have the capacity to act as a neuroprotective agent. These have the ability to reverse neuropathic pain induced by chemotherapy. The Patent allows Kannalife the liberty to advance their exploration of the application and possibilities of its novel molecular entities (NMEs) on a wide spectrum of disease indications manifested as neurodegeneration, oxidative stress, and chronic pain.

CEO of Medical Marijuana, Inc, Dr. Stuart Titus expressed his joy at getting this patent, which has pushed the company to a different league,

We’re proud of Kannalife’s team for the amount of significant progress they’ve made with KLS-13019 over the past few years. As the FDA and other national regulatory bodies call for more cannabis and cannabinoid-related research studies in 2020, this new patent furthers Kannalife as a global research leader in the emerging field of cannabinoid therapeutics.

The Patent issued by China is in lieu with the series of growing intellectual property estate of the international WIPO/PCT Patent titled “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” (the “PCT Patent”). Since the first PCT Patent filing in 2015, Kannalife has managed to get patent approval from three noteworthy international authorities:

Two U.S. Patents for “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy” and “Method for treating hepatic encephalopathy or a disease associated with free radical mediate stress and oxidative stress with novel functionalized 1,3-benzene diols,” respectively. A Japanese Patent “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy,” and Russian Patent “Novel Functionalized 1,3-Benzene Diols and their Method of Use for the Treatment of Hepatic Encephalopathy.” The latest addition to this list is the Chinese Patent that the company announced in a tweet.